Work

Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)

Year: 2020

Type: article

Source: Blood

DOI: 10.1182/blood-2020-139315

Authors: Rakesh Popat, Aikaterini Kazantzi, Asim Farooq, Praneetha Thulasi, Sagar Lonial, Andrzej Jakubowiak, Ashraf Z. Badros, Bennie H. Jeng, Joanna Opalinska, January Baron, Trisha Piontek, Julie Byrne, Lynsey Womersley, Ira Gupta, Simona Degli Esposti

Institutions: University College London Hospitals NHS Foundation Trust, University of Chicago, Emory University, Emory Eye Center, Winship Cancer Institute, University of Maryland, Baltimore, GlaxoSmithKline (United States), Moorfields Eye Hospital NHS Foundation Trust, NIHR Moorfields Biomedical Research Centre, University College London

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3097230553

FWCI: 0.316

Cites:

Cited by: 3

Related to: 10